
    
      30 eyes will be randomized in a 1:2 ratio (Group A= 10 patients; Group B= 20 patients) Group
      A: ("monthly group")- Consented patient with enrolled eye will receive 12 monthly required
      injections of 0.3mg ranibizumab over 1 year OR Group B: ("As needed (PRN) Group")- Consented
      patient with enrolled eye will receive 6 monthly required injections of 0.3mg ranibizumab for
      6 months, followed by as needed (PRN) dosing (required ranibizumab if DME persistent on
      Optical Coherence Tomography (OCT) and Early Treatment Diabetic Retina Study (ETDRS) Best
      Corrected Visual Acuity (BCVA) <20/20) for 6 months.
    
  